Angiogenesis Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Angiogenesis Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Angiogenesis
New angiogenesis data have been reported by M.S. Duh and co-authors
November 6th, 2009
According to a study from the United States, "Angiogenesis inhibitors ( AI) are promising novel treatments for patients with renal cell carcinoma (RCC). However, IV therapy may impose infection risk from IV catheters, and will include increased costs due to administration and transportation costs." "This study evaluated the incremental costs associated with IV administration of selected AI therapies (bevacizumab off-label) compared to oral therapies (sunitinib or sorafenib) for the treatment of RCC. Patients with >= 2 RCC claims (ICD-9: 189.0, 198.0) were identified from a US commercial health insurance claims database from 1/2004 to 12/2007. receiving bevacizumab (n...
Source: Angiogenesis Weekly (2009-11-06)
|
